Web Desc
Targeted Protein Degradation
joint with Ubiquitin Biology
Scientific Organizers: Rajesh Chopra, Nathanael Gray, Anita Gandhi and Georg Winter
Date: March 29 - April 01, 2020
Location: Snowbird Resort, Snowbird, UT, USA
Sponsored by Incyte Corporation and Novartis Institutes for BioMedical Research
Summary of Meeting:
This Keystone Symposia conference will highlight the recent exciting advances in targeting proteins for degradation as an alternative to conventional inhibitory small molecules and antibodies. Protein degradation can be undertaken by bifunctional molecules that bind the target for ubiquitin-mediated degradation by complexing them with Cereblon (CRBN), von Hippel-Lindau or other E3 ligases. Alternatively, ligase receptors such as CRBN or DCAF15 can also be used as a ‘template’ to bind IMiD or sulphonamide-like compounds to degrade multiple context specific proteins by the selected E3 ligases. The ‘template approach’ results in the degradation of neo-substrates, some of which would be difficult to drug using conventional approaches. The chemical properties necessary for drug discovery, the rules by which neo-substrates are selected by ligase receptors and defining the optimal components of the ubiquitin proteasome for protein degradation are still to be fully elucidated. This conference will bring together early pioneers in the field, emerging scientists and experts from industry and academics to describe how these challenges are being addressed. Furthermore, experts who have used IMiD agents and proteasome inhibition in the clinic in real world practical applications of protein degradation agents have been invited to speak at this conference. Another unique aspect of this conference is with it being paired with the Keystone Symposia conference on Ubiquitin Biology. Protein ubiquitination regulates nearly every critical cellular pathway and emerging evidence has demonstrated that defects within the ubiquitin proteasome system can directly lead to human disease. This has fueled a recent expansion of drug development efforts to harness the ubiquitin proteasome system to both aid in its functionality during disease progression and to specify individual targets for degradation. By pairing these meetings, participants will be able to network and foster new collaborations between these two related areas of science.
DEADLINES:
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Deadline: November 21 2019 details
Discounted Abstract Deadline: November 21 2019 details & pricing
Abstract Deadline: December 19 2019 details & pricing
Discounted Registration Deadline: January 29 2020 details & pricing


Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.


Registered attendees of one meeting in a joint pair may participate in sessions of the other, pending space availability.


Keystone Symposia thanks our Sponsor for generously supporting this meeting:
Incyte CorporationNovartis Institutes for BioMedical Research
We gratefully acknowledge additional support for this conference from:
Tocris Bioscience, a Bio-Techne Brand
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Novartis Institutes for BioMedical Research
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found